GlycoNex puts ADC targeting aberrant glycosylation into first-in-human for GI cancers

GlycoNex, Inc. (4168), a Taiwan-based clinical-stage biotechnology company, [announced](https://www.prnewswire.com/news-releases/glyconex-receives-pmda-approval-in-japan-to-initiate-first-in-human-phase-1-trial-of-gnx1021-in-gastrointestinal-cancers-302741147.html) on April 14 that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has cleared the initiation of a first-in-human Phase I trial of GNX1021, its lead antibody-drug conjugate (ADC) candidate, in patients with advanced gastrointestinal cancers. Enrollment at Japanese sites is expected to begin in June 2026, with a Taiwan IND submission planned for the same month and enrollment there anticipated in the third quarter of 2026. The multicenter Phase I study will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of GNX1021 across dose escalation cohorts, with the primary objective of establishing a recommended dose for subsequent development. Patient numbers, specific endpoints beyond dose-finding, and an anticipated completion date have not been disclosed. GNX1021 targets the bLeB/Y antigen, a branched glycan structure abnormally overexpressed on the surface of epithelial tumor cells, including those of gastric, pancreatic, and colorectal origin, while showing limited expression in normal tissue. The molecule's mechanism departs from conventional ADC design. Rather than coupling a cytotoxic payload to an antibody directed at a single protein epitope, GNX1021 exploits aberrant glycosylation patterns shared across multiple tumor-associated membrane proteins. This multi-target engagement is intended to reduce the escape routes available to heterogeneous tumor cell populations — a problem that has constrained the durability of responses seen with single-target agents in gastric cancer. GlycoNex [published preclinical data](https://app.allsci.com/article/ASC-PB-0000266194747-1.0-1758113272) for the molecule at the American Association for Cancer Research (AACR) Annual Meeting 2025. ### Research context The biological rationale for glycan-directed therapy in gastrointestinal malignancies rests on a well-characterized feature of cancer cell biology: aberrant glycosylation. Tumor cells frequently display truncated or branched carbohydrate structures — including Lewis blood group-related antigens such as the bLeB/Y epitope — that are absent or minimally expressed on healthy epithelium. This differential expression creates a targeting window that protein-directed therapies cannot exploit when the relevant protein is also present on normal tissue. The ADC format allows GlycoNex to combine this selectivity with direct cytotoxic delivery, potentially improving the therapeutic index relative to unconjugated antibodies. Tumor heterogeneity remains a central obstacle in gastric cancer, where intra-tumoral variation in HER2 and Claudin 18.2 (CLDN18.2) expression has been linked to resistance and relapse following targeted therapy. A glycan target broadly expressed across multiple surface proteins, if validated clinically, could theoretically maintain activity across heterogeneous cell populations within the same tumor — a mechanistic advantage that protein-targeted ADCs structurally cannot replicate. The PMDA clearance positions Japan as the entry point for GNX1021's human testing, consistent with Japan's role as a regionally important trial site for gastrointestinal oncology programs given its high gastric cancer incidence. Whether the glycan-targeting strategy translates into clinical activity will depend on the Phase I data now set to emerge from 2026 onward. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/gnx1021-phase-1-trial-glyconexs-targets-aberrant)